STOCK TITAN

electroCore to Announce Third Quarter Ended September 30, 2020 Financial Results on Thursday, November 12

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Conference Call to be Held at 4:30pm Eastern Time

BASKING RIDGE, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the third quarter ended September 30, 2020 after the close of the market on Thursday, November 12, 2020. Management will host a conference call and webcast at 4:30pm Eastern Time to discuss the financial results and answer questions.

Thursday, November 12 @ 4:30pm Eastern Time

Domestic:877-407-4018
International: 201-689-8471
Conference ID:13711577
Webcast:http://public.viavid.com/index.php?id=141806

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.

For more information, visit www.electrocore.com.

Investors:
Hans Vitzthum
LifeSci Advisors
617-430-7578
hans@lifesciadvisors.com

or

Media Contact:
Jackie Dorsky
electroCore
973-290-0097
jackie.dorsky@electrocore.com

electroCore, Inc.

NASDAQ:ECOR

ECOR Rankings

ECOR Latest News

ECOR Stock Data

41.06M
4.17M
18.51%
16.59%
0.17%
Electromedical and Electrotherapeutic Apparatus Manufacturing
Manufacturing
Link
United States of America
ROCKAWAY

About ECOR

electrocore is, a us based electroceutical healthcare company, which is developing a range of non-invasive vagus nerve stimulation (nvns) patient administered therapies for the treatment of multiple conditions in neurology, psychiatry, gastroenterology and other fields. initial focus is on primary headache (migraine and cluster headache), with trials continuing in epilepsy, gastric motility disorders, depression and anxiety. electrocore, which was founded in 2005, has more than 30 employees and full time consultants with offices in the us (head office), germany (german and european head office), uk, italy, australia, and canada.